Total Payments
$1,320
2024 Payments
$148.24
Companies
22
Transactions
70
Medicare Patients
1,761
Medicare Billing
$153,898
Payment Breakdown by Category
Food & Beverage$1,320 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,320 | 70 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $226.33 | 12 | $0 (2020) |
| Astellas Pharma US Inc | $169.34 | 9 | $0 (2019) |
| Novo Nordisk Inc | $169.30 | 4 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $160.18 | 11 | $0 (2020) |
| ABBVIE INC. | $144.67 | 10 | $0 (2024) |
| Amarin Pharma Inc. | $99.77 | 1 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $42.50 | 3 | $0 (2018) |
| Allergan, Inc. | $41.40 | 3 | $0 (2020) |
| Bausch Health US, LLC | $39.92 | 2 | $0 (2019) |
| Valeant Pharmaceuticals North America LLC | $30.15 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $148.24 | 3 | Novo Nordisk Inc ($133.89) |
| 2023 | $16.97 | 1 | AbbVie Inc. ($16.97) |
| 2021 | $14.12 | 1 | Biohaven Pharmaceuticals, Inc. ($14.12) |
| 2020 | $88.81 | 7 | Allergan, Inc. ($41.40) |
| 2019 | $467.89 | 23 | Amgen Inc. ($213.19) |
| 2018 | $207.83 | 15 | AbbVie, Inc. ($70.15) |
| 2017 | $376.34 | 20 | Astellas Pharma US Inc ($127.64) |
All Payment Transactions
70 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/24/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $119.21 | General |
| Category: Obesity | ||||||
| 06/04/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $14.68 | General |
| Category: Obesity | ||||||
| 03/19/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $14.35 | General |
| Category: NEUROSCIENCE | ||||||
| 12/18/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: NEUROSCIENCE | ||||||
| 04/19/2021 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: PRIMARY CARE | ||||||
| 08/27/2020 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $11.54 | General |
| Category: Central Nervous System | ||||||
| 08/13/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: NEUROSCIENCE | ||||||
| 03/09/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.42 | General |
| Category: NEUROSCIENCE | ||||||
| 02/13/2020 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $11.62 | General |
| Category: Neuroscience | ||||||
| 02/10/2020 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $11.11 | General |
| Category: AED | ||||||
| 01/31/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.06 | General |
| Category: NEUROSCIENCE | ||||||
| 01/07/2020 | Amgen Inc. | Aimovig (Biological), Repatha | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: Neuroscience | ||||||
| 10/23/2019 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $12.60 | General |
| Category: UROLOGY | ||||||
| 10/07/2019 | JAZZ PHARMACEUTICALS INC. | SUNOSI (Drug) | Food and Beverage | In-kind items and services | $12.92 | General |
| Category: PAIN | ||||||
| 10/02/2019 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $12.60 | General |
| Category: Neuroscience | ||||||
| 10/01/2019 | Amgen Inc. | Aimovig (Biological), Repatha | Food and Beverage | In-kind items and services | $12.61 | General |
| Category: Neuroscience | ||||||
| 08/21/2019 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $78.27 | General |
| Category: Neuroscience | ||||||
| 08/16/2019 | Bausch Health US, LLC | WELLBUTRIN (Drug), APLENZIN | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: NEUROLOGY | ||||||
| 08/01/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $13.70 | General |
| Category: AED | ||||||
| 07/25/2019 | Amgen Inc. | Aimovig (Biological), Repatha | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: Neuroscience | ||||||
| 07/25/2019 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: Neuroscience | ||||||
| 05/24/2019 | Bausch Health US, LLC | WELLBUTRIN (Drug), APLENZIN | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: NEUROLOGY | ||||||
| 05/23/2019 | ARBOR PHARMACEUTICALS, INC. | Edarbi (Drug) | Food and Beverage | In-kind items and services | $12.14 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/20/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $11.87 | General |
| Category: AED | ||||||
| 05/10/2019 | Amgen Inc. | Aimovig (Biological), Repatha | Food and Beverage | In-kind items and services | $11.40 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 405 | 539 | $64,228 | $43,019 |
| 2022 | 7 | 454 | 566 | $64,356 | $41,557 |
| 2021 | 7 | 486 | 627 | $62,054 | $41,447 |
| 2020 | 6 | 416 | 516 | $45,474 | $27,876 |
Total Patients
1,761
Total Services
2,248
Medicare Billing
$153,898
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 110 | 110 | $17,013 | $14,860 | 87.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 122 | 215 | $23,226 | $13,299 | 57.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 104 | 145 | $22,103 | $13,013 | 58.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 34 | 34 | $1,169 | $1,145 | 98.0% |
| 90688 | Influenza vaccine, quadrivalent, 0.5 ml dosage | Office | 2023 | 35 | 35 | $716.80 | $702.45 | 98.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 115 | 170 | $26,856 | $15,979 | 59.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 95 | 95 | $15,365 | $13,165 | 85.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 117 | 173 | $19,428 | $9,838 | 50.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 44 | 44 | $1,498 | $1,468 | 98.0% |
| 90688 | Influenza vaccine, quadrivalent, 0.5 ml dosage | Office | 2022 | 42 | 42 | $859.02 | $842.62 | 98.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 15 | 15 | $268.35 | $184.14 | 68.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 26 | 27 | $81.00 | $80.46 | 99.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 135 | 223 | $24,868 | $14,316 | 57.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 101 | 136 | $21,654 | $13,282 | 61.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 82 | 82 | $13,219 | $11,615 | 87.9% |
| 90688 | Vaccine for influenza for administration into muscle, 0.5 ml dosage, quadrivalent | Office | 2021 | 46 | 47 | $934.29 | $934.29 | 100.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 45 | 46 | $897.42 | $897.42 | 100.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 65 | 80 | $240.00 | $240.00 | 100.0% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 12 | 13 | $240.37 | $161.70 | 67.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 98 | 137 | $18,376 | $10,062 | 54.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 65 | 65 | $9,305 | $8,026 | 86.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 113 | 169 | $15,656 | $7,843 | 50.1% |
| 90688 | Vaccine for influenza for administration into muscle, 0.5 ml dosage | Office | 2020 | 47 | 48 | $1,087 | $916.78 | 84.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 45 | 46 | $897.40 | $875.54 | 97.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 48 | 51 | $153.00 | $151.98 | 99.3% |
About Dr. Sirike Aasmaa, DO
Dr. Sirike Aasmaa, DO is a Internal Medicine healthcare provider based in Montville, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1861549925.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sirike Aasmaa, DO has received a total of $1,320 in payments from pharmaceutical and medical device companies, with $148.24 received in 2024. These payments were reported across 70 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($1,320).
As a Medicare-enrolled provider, Aasmaa has provided services to 1,761 Medicare beneficiaries, totaling 2,248 services with total Medicare billing of $153,898. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Montville, NJ
- Active Since 01/04/2007
- Last Updated 07/08/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1861549925
Products in Payments
- Aimovig (Biological) $226.33
- TROKENDI XR (Drug) $160.18
- Wegovy (Drug) $133.89
- Myrbetriq (Drug) $127.64
- Vascepa (Drug) $99.77
- UBRELVY (Drug) $72.72
- Synthroid (Drug) $57.06
- Creon (Drug) $56.29
- JANUVIA (Drug) $42.50
- WELLBUTRIN (Drug) $39.92
- Saxenda (Drug) $35.41
- XIFAXAN (Drug) $30.15
- VESICARE (Drug) $29.10
- FLUZONE HIGH-DOSE (Drug) $27.47
- TREXIMET (Drug) $18.90
- BEVESPI AEROSPHERE (Drug) $17.14
- Welchol (Drug) $17.10
- VYVANSE (Drug) $14.89
- XARELTO (Drug) $14.18
- NURTEC ODT (Drug) $14.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.